Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation

Inclusion Criteria: * Patients ≥18 years of age undergoing allogeneic liver transplantation * Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Written informed consent prior to any study procedures Exclusion Criteria: * Known allergies to bovine or porcine products or any other ingredients of the product * Patients older than 65 years of age * Patients listed in a high-urgency status that would not allow proper preparation of the study interventions * Patients receiving a secondary liver graft (Re-Transplantation) * Double organ transplant recipients * Pre-existing renal failure that requires or has required hemodialysis within the last year * Pulmonary function: FEV1, FVC, DLCO ≤50% predicted * Cardiac function: left ventricular ejection fraction ≤50% * HIV seropositive, varicella virus active infection or any other clinically relevant infection * History of any malignancy (including lymphoproliferative disease and hepatocellular carcinoma) except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence * Unstable myocardium (evolving myocardial infarction), cardiogenic shock * Females of childbearing potential (hormonal status and gynecological consultation required) * Patients with portal vein thrombosis * Patients with a history of pulmonary embolism